Patient-centred healthcare company Temedica raises €25M

- Advertisement -

Company develops digital companion for various diseases to receive patient-generated data

- Advertisement -

Temedica was founded with the aim of supporting patients with personalized medicine: the company creates digital companions for patients who have diseases such as multiple sclerosis, psoriasis and cancer; The company then uses the data generated from those apps to understand how the patient is doing to help them through their healthcare journey.

- Advertisement -

On Wednesday, the company announced a €25 million Series B funding round led by the Munich-based family office, alongside existing investor MIG Capital, to expand its real-world insights ecosystem. With this round, the company has now raised a total of €42 million.

Founded in 2016, Munich, Germany-based Temedica brands a different app, rather than one app that covers every situation and tries to have one size fits all approaches. The idea is to give patients the opportunity to be treated individually and to support personalized medicine.

- Advertisement -

Through its personalized apps, the company is able to individually inform the patient how best to manage their condition, but also learn a lot from the larger patient cohort, gaining new insights and evidence across the entire life science value chain. Do what he feeds into his real. -World Insights Platform, called Permia.

Temedica’s apps are not intended to improve outcomes for patients; Instead, it builds apps to give patients the opportunity to better care for their health, with the main goal being to generate patient-generated data and contribute to the latest science.

Part of the solution also includes partnering with pharmaceutical companies; For example, the company has teamed up with Roche for multiple sclerosis and Bristol Myers Squibb for psoriasis.

Through these partnerships, pharma companies gain access to the real-world evidence data Temedica collects, which provides them with insights they would not normally have, resulting in an opportunity to understand how patient How are treatments on the side, how are they being understood, how are they being consumed, and how effective are they.

To date, Temedica has collected 40 billion data points on over 50,000 diagnoses.

“Temedica’s vision is to make pioneering contributions to the development of personalized medicine by connecting health-relevant data to new, evidence-based insights. We are convinced that large data sets and entirely new types of data play an important role in this, such as Temedica’s “As patient-generated data from large populations outside of classic clinical trials,” Gloria Seibert, founder and CEO of Dr.

“These enable entirely new knowledge and understanding of diseases and their true course. I am very pleased that our investors share this vision and accompany and support us as we continue to expand the Temedica ecosystem. Let’s continue.”

Listen to an interview with Siebert that VeterNews did earlier this year.

(Image source:

Source link

- Advertisement -

Recent Articles

Related Stories